Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, England--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities in Africa through research, advanced molecular diagnostics and clinical programs.

Illumina Collaborates With 54gene in the Creation of a World-Class Genomics Facility in Nigeria

SAN DIEGO--(BUSINESS WIRE)--Illumina Welcomes Kathryne Reeves as Chief Marketing Officer

Illumina Welcomes Kathryne Reeves as Chief Marketing Officer

Cushman & Wakefield plc

Proto Labs

Stoneridge

If you own a toxic stock for long, you are likely to see a big loss in your wealth. Discarding them at the right time is the key to shield your portfolio from big losses.

4 Toxic Stocks to Discard From Your Portfolio Right Now

Illumina shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Stock Upgrades: Illumina Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Illumina Shows Rising Relative Strength

Illumina shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Illumina Shows Improved Relative Strength; Still Shy Of Benchmark appeared first on Investor's Business Daily.

Illumina Shows Improved Relative Strength; Still Shy Of Benchmark

Illumina Revenue Decline, And Other News: The Good, Bad And Ugly Of Biopharma

Investors were not pleased with the company’s second-quarter financial results.

Why Illumina Stock Is Plunging Today

Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.

Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline

Illumina Inc. (ILMN) CEO Francis deSouza on Q2 2020 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (Nasdaq:ILMN).

Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome

Illumina (ILMN) delivered earnings and revenue surprises of -13.89% and -6.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Lags Q2 Earnings and Revenue Estimates

Shares of Illumina Inc. ILMN, -0.35% fell more than 13% in the late session after the biotech company reported second-quarter results shy of Wall Street expectations and said many of its research clients remain closed due to the pandemic.

Illumina stock falls 13% on Q2 results shy of expectations

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020.

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020

Illumina is in a potential buy range with its next quarterly report on tap for Aug. 6. The stock is right around a 377.90 buy point from a first-stage flat.

Stocks To Watch With Earnings Approaching: Illumina

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Illumina (ILMN) Q2 Earnings Expected to Decline

Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.

Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?

Abbott Labs

Bristol-Myers

These companies have proven they can rebound from the worst.

3 Rock-Solid Healthcare Stocks to Buy in a Market Crash

BioMarin Pharmaceutical

Vertex Pharmaceuticals

The healthcare industry is a good place to shop for stocks to keep your portfolio healthy during the next market crash.

3 Unstoppable Stocks to Buy Before the Next Market Crash

Is this genomics giant worth a second look?

Is Illumina Stock a Buy?

After an 80% rise since the March lows of this year, at the current price of around $375 per share we believe Illumina, best known for its genetic variation and biological function systems, is fully valued based on its historic P/E multiples. ILMN stock has rallied from $210 to $375 off the recent.

What’s Next For Illumina After An 80% Rally?

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Q2 2020 Earnings Release Date Announcement

Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020

The stock price of Illumina, best known for its genetic variation and biological function systems, has rallied around 56% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $370 after falling to a low of $238 in late March as a rapid increase in the number of Covid-19.

After 56% Rally Can Illumina Stock See More Gains?

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite. TruSight Software delivers ready-made infrastructure to realize the full potential of whole-genome sequencing for rare genetic diseases. This new offering enables sample-to-report analysis for genetic disease testing, giving customers an integrated solution that focuses on one

Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases

Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.

Here's Why You Should Hold on to Illumina Stock for Now

Since its launch in 1998 Illumina and its genetic analysis toolkits and services have become an essential component of the new biological manufacturing and therapeutic development industries which have emerged in the last twenty five years. And for the past six years the company has attempted to encourage the development of the industry through an […]

News for Illumina Stock (ILMN)